Immunogenicity of Two Efficacious Outer Membrane Protein‐Based Serogroup B Meningococcal Vaccines among Young Adults in Iceland

Citations Over TimeTop 10% of 1998 papers

Abstract

Serum bactericidal activity (SBA) and ELISA antibody levels elicited by two efficacious serogroup B meningococcal vaccines were measured in a controlled trial involving 408 15- to 20-year-olds. Subjects were given two doses at a 6-week interval of a serogroup B or control vaccine. Response was defined as > or = 4-fold rise in antibody level. After two doses of the Finlay Institute (Havana) vaccine at 12 months, the proportions of SBA and ELISA responders were not different from those of the control group (15% and 17% [vaccine] vs. 13% and 9% [control], P > .05). After two doses of the National Institute of Public Health (Oslo) vaccine, there were more SBA and ELISA responders than in the control group (47% and 34% [vaccine] vs. 10% and 1% [control]) or the Finlay Institute vaccine group (P < .05 for both). SBA and ELISA may be insensitive correlates for protective efficacy for some outer membrane protein-based serogroup B meningococcal vaccines.

Related Papers

• → Evidence for Indirect Nosocomial Transmission of Neisseria meningitidis Resulting in Two Cases of Invasive Meningococcal Disease(2006)13 cited
• → Cross-linking analysis of antigenic outer membrane protein complexes of Neisseria meningitidis(2005)20 cited
• → Immunogenicity of Serogroup A and C Neisseria meningitidis Polysaccharide Vaccines Administered Together in Humans(1978)6 cited
• → Outer Membrane Proteins and Serosubtyping with Outer Membrane Vesicles from Clinical Isolates of Neisseria meningitidis(1997)7 cited
• → Binding characteristics and immunogenicity of modified factor H binding protein from Neisseria meningitidis(2010)